Chapter 433 - 261: Academician Zeng’s Promise and Teacher Wu’s Training Camp
Chapter 433: Chapter 261: Academician Zeng’s Promise and Teacher Wu’s Training Camp
Dean Chen, Director Fu, Director Ma, and Jin Yu arrived at Qinghe City Jiuhua Hospital and found Ma Mengchao of the Hepatic Tumor Surgery department.
Ma Mengchao was quite surprised by the arrival of these experts.
In his office, Ma Mengchao sat on the sofa, looking at his guests. He prepared tea for them while listening to the purpose of their visit.
Dean Chen glanced at Fu Jinfen. Of everyone present, Director Fu had the closest working relationship with Wu Ting.
Director Fu took out a stack of documents. It contained Professor Long’s postoperative serum levels for ALT, TBIL, AFP, and HBV DNA, as well as Li Ai’s previous postoperative follow-up information.
Wu Ting’s phase-three treatment method for HBV-related primary hepatocellular carcinoma only had one case so far—Professor Long. However, a large amount of case data had already been collected for the phase-two treatment method.
Director Fu spoke to Ma Mengchao with excitement:
"Professor Ma, look. This is a summary of the prognoses for patients with HBV-related primary hepatocellular carcinoma that our department has recently treated in collaboration with Wu Ting. It also includes the latest postoperative recovery status of the phase-three patient, Professor Long."
Ma Mengchao took the documents and examined them carefully. As he read through the details, he was profoundly shaken.
"As of now, we can basically declare phase two a success. Meanwhile, Wu Ting’s phase-three therapy has officially entered clinical trials. He and the R&D team, reorganized from the former Jin Pharmaceutical Group, have also developed the new drug Fengmu Tiada under his leadership."
"So, the few of us discussed it and wanted to talk with you about scheduling a meeting with Scholar Zeng."
"We believe Wu Ting’s results have established a solid foundation. The next step should be to provide strong support and promote it."
"Currently, the Hepatic Tumor Surgery departments of Jin Province Tumor Hospital, Haijin Port, Xianglin City Xuanshang University Affiliated Tumor Hospital, and Saint An Hospital are all preparing to collaborate with Wu Ting’s team. We plan to introduce Fengmu Tiada into first-line clinical use and jointly advance Wu Ting’s phase-three therapy."
"We also plan to arrange a dedicated training session with Wu Ting during this time. Once each of our teams has mastered his phase-three therapy, we will officially roll it out in our clinical practices."
"We want to complete the clinical validation for this phase-three therapy as quickly as possible and assist him in launching the fourth phase."
"Our idea is to complete the development of Wu Ting’s radical cure for HBV-related primary hepatocellular carcinoma through the cooperation of our several hospitals. We also want to create a corresponding set of guidelines, establishing Jin Country’s own clinical guidelines for HBV-related primary hepatocellular carcinoma!"
Hearing the plan from Fu Jinfen and the other directors, Ma Mengchao was in disbelief.
’A complete radical cure for HBV-related primary hepatocellular carcinoma, and creating clinical guidelines at the same time?’
’That’s a massive undertaking! It would require an enormous investment of manpower, resources, and time!’
Ma Mengchao had his doubts. Besides, with several hospitals working together, wouldn’t it just become a disorganized mess?
Director Fu and the others had already given Ma Mengchao’s concerns a great deal of thought.
Director Fu took out his phone and showed a video: the public recording of a surgery performed by Wu Ting’s team.
"This is the latest lab version of the WD large-scale model and database. Wu Ting’s team added a brand-new function to the database that can integrate data from different teams, different Technicians, different patients, and different surgical procedures from all networked hospitals."
"By using big data and AI deep learning, it boosts efficiency by millions of times, integrating all the data to generate standardized surgical procedures, clinical points of attention, and optimal surgical plans."
"So, in principle, we just need to use official channels to deploy this system from Wu Ting’s team into the operating rooms of every hepatic tumor surgery department. With every new team that joins and every surgery that is completed—successful or not—a new set of data will be added. The more teams that connect and the more surgeries that are performed, the faster we can generate the clinical guidelines for a radical cure of HBV-related primary hepatocellular carcinoma."
"Furthermore, these clinical guidelines will be constantly optimized and iterated. They exist as a database and can be directly applied to the surgeries of every team, every Technician, and every patient in the future."
"Isn’t that far more efficient, direct, and meaningful than ordinary clinical guidelines!"
After he finished speaking, Director Fu looked at Ma Mengchao with a solemn expression.
"Professor Ma, that’s why we’ve come this time. We hope you will take us to see Scholar Zeng to get his approval for this massive project."
"To ensure this project has official backing and authority, we want to ask Scholar Zeng to take the lead at this year’s Jin Country Medical Association’s surgical conference. We propose forming a dedicated Hepatic Tumor Surgery task force at the national level, with Wu Ting’s team at its core!"
"We want to appoint Wu Ting as the head of this task force and invite expert professors from the field of hepatobiliary surgery across the country to join. They would lead their respective teams to connect to the database and work together to promote and popularize Wu Ting’s radical cure for HBV-related primary hepatocellular carcinoma."
"And before Scholar Zeng makes his decision, the departments from our four hospitals are willing to act as a pilot program. There’s still some time before this year’s annual conference, which is enough for us to complete the phase-three validation."
"As long as we have Scholar Zeng’s leadership and the Hepatic Tumor Surgery task force is established, we believe the fourth phase can also be launched quickly. If we can truly complete the R&D for all four phases as projected, this will be a monumental achievement that benefits the nation and its people for generations to come!"